LTGO 33
Alternative Names: LTGO-33Latest Information Update: 07 Oct 2024
At a glance
- Originator Latigo Biotherapeutics
- Class Non-opioid analgesics; Small molecules
- Mechanism of Action Nav1.8 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pain
Most Recent Events
- 05 Aug 2024 Pharmacodynamics data from preclinical trial in pain were presented at the 20th World Congress on Pain (IASP-2024)
- 30 Apr 2024 Preclinical trials in Pain in USA (unspecified route), prior to April 2024 (Latigo Biotherapeutics pipeline, April 2024)
- 30 Apr 2024 Pharmacodynamics data from a preclinical trial in Pain released by Latigo Biotherapeutics (Latigo Biotherapeutics website, April 2024)